Jialin Mao1, Suzanne Tay2, Cyrus S Khojasteh2, Yuan Chen2, Cornelis E C A Hop2, Jane R Kenny2. 1. Department of Drug Metabolism and Pharmacokinetics, Genentech, A Member of the Roche Group, 1 DNA Way, South San Francisco, California, 94080, USA. mao.jialin@gene.com. 2. Department of Drug Metabolism and Pharmacokinetics, Genentech, A Member of the Roche Group, 1 DNA Way, South San Francisco, California, 94080, USA.
Abstract
PURPOSE: To evaluate an alternative in vitro system which can provide more quantitatively accurate drug drug interaction (DDI) prediction for 10 protein kinase inhibitors for which DDI risk was over-predicted by inhibition data generated in human liver microsomes (HLM). METHODS: Three cryopreserved human hepatocyte (hHEP) systems: 1) plated hHEPs; 2) hHEPs suspended in Dulbecco's Modified Eagle Medium (DMEM) and 3) hHEPs suspended in human plasma (plasma hHEPs) were developed to detect CYP3A time dependent inhibition, and the static mechanistic model was used to predict clinical outcomes. RESULTS: A general trend was observed in the CYP3A inactivation potency (k inact /K I, app ) as HLM > plated > DMEM ≥ plasma hHEPs. Using the static mechanistic model, DDIs predicted using parameters estimated from plated, DMEM and plasma hHEPs had 84, 74 and 95% accuracy (out of 19 clinical interaction studies) within 2-fold of the reported interaction, respectively. They demonstrated significant improvement compared to the DDIs predicted using parameters estimated from HLMs where 58% accuracy was obtained. CONCLUSIONS: Based on 19 DDIs, plasma hHEPs demonstrate a more reliable clinical DDI prediction for 10 protein kinase inhibitors and prototypical CYP3A time dependent inhibitors.
PURPOSE: To evaluate an alternative in vitro system which can provide more quantitatively accurate drug drug interaction (DDI) prediction for 10 protein kinase inhibitors for which DDI risk was over-predicted by inhibition data generated in human liver microsomes (HLM). METHODS: Three cryopreserved human hepatocyte (hHEP) systems: 1) plated hHEPs; 2) hHEPs suspended in Dulbecco's Modified Eagle Medium (DMEM) and 3) hHEPs suspended in human plasma (plasma hHEPs) were developed to detect CYP3A time dependent inhibition, and the static mechanistic model was used to predict clinical outcomes. RESULTS: A general trend was observed in the CYP3A inactivation potency (k inact /K I, app ) as HLM > plated > DMEM ≥ plasma hHEPs. Using the static mechanistic model, DDIs predicted using parameters estimated from plated, DMEM and plasma hHEPs had 84, 74 and 95% accuracy (out of 19 clinical interaction studies) within 2-fold of the reported interaction, respectively. They demonstrated significant improvement compared to the DDIs predicted using parameters estimated from HLMs where 58% accuracy was obtained. CONCLUSIONS: Based on 19 DDIs, plasma hHEPs demonstrate a more reliable clinical DDI prediction for 10 protein kinase inhibitors and prototypical CYP3A time dependent inhibitors.
Entities:
Keywords:
CYP3A; drug–drug interaction; kinase inhibitors; prediction; time dependent inhibition
Authors: Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh Journal: Pharm Res Date: 2012-03-14 Impact factor: 4.200
Authors: Keith T Flaherty; Chetan Lathia; Reginald F Frye; Lynn Schuchter; Maryann Redlinger; Mark Rosen; Peter J O'Dwyer Journal: Cancer Chemother Pharmacol Date: 2011-02-25 Impact factor: 3.333
Authors: Daniel T Milton; Gregory J Riely; Christopher G Azzoli; Jorge E Gomez; Robert T Heelan; Mark G Kris; Lee M Krug; William Pao; Barbara Pizzo; Naiyer A Rizvi; Vincent A Miller Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: K T Olkkola; K Aranko; H Luurila; A Hiller; L Saarnivaara; J J Himberg; P J Neuvonen Journal: Clin Pharmacol Ther Date: 1993-03 Impact factor: 6.875
Authors: Stephen Fowler; Peter N Morcos; Yumi Cleary; Meret Martin-Facklam; Neil Parrott; Michael Gertz; Li Yu Journal: Curr Pharmacol Rep Date: 2017-02-01